The impact of TP53 and PTEN tumor suppressor genes on response to different breast cancer treatment modalities
Introduction. Breast cancer (BC) is the most frequent type of malignancy and the leading cause of cancer related death among women worldwide. BC is exceptionally heterogeneous disease and therefore distinct treatment modalities are necessary to address these differences. The aim of our study was to investigate the impact of TP53 and PTEN tumor supp...
By Nikola Tanić, Tatjana Dramićanin, Nejla Ademović, Tijana Tomić, Blagoje Murganić, Zorka Milovanović, Milica Nedeljković, Nasta Tanić
Neoadjuvant therapy for HER2-positive breast cancer
The human epidermal growth receptor 2 (HER2, c-erb-B2) is present in 15-20% of breast cancer at the time of diagnosis. Overexpression of HER2 receptor is associated with more aggressive form of breast cancer. Trastuzumab is a human monoclonal antibody that blocks the signaling pathways of cell proliferation by binding to the HER2 receptor. Due to t...
By Dragana Jokanović, Slađana Popović, Olivera Čančar
Importance of neoadjuvant treatment in management of locally advanced rectal cancer
Neoadjuvant approach or preoperative use of radiotherapy and chemotherapy in the treatment of locally advanced rectal cancer has led to a significant improvement in local control of the disease by reducing the percentage of local recidives. Furthermore, it has improved the quality of life since the number of sphincter sparing resections has been in...
By